Botanix is an ASX-listed dermatology company based in Philadelphia and Phoenix (USA) that is committed to the development and commercialisation of novel treatments for common skin diseases and infections.
The Company’s lead product is a novel treatment for primary axillary hyperhidrosis, a medical condition where excessive sweating occurs beyond what is needed to maintain body temperature, which impacts the lives of more than 15 million people in the US alone. This product is backed by successful Phase 3 clinical studies, is already approved in Japan, and is in the final stages of US regulatory clearance.
The broader clinical pipeline targets unmet needs in dermatology (including acne, rosacea and dermatitis) as well as infections, and are underpinned by well-controlled, randomised clinical trials.
Botanix has attracted a world-class team and significant capital to support the development and commercialisation of its products.
Company Details
- Employees
- 53
- Address
- Level 1, 50 Angrove Street,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- botanixpharma.com
- HQ
- North Perth, WA
Botanix Pharmaceuticals Questions
Botanix Pharmaceuticals's website is botanixpharma.com
Botanix Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/botanix-pharmaceuticals
Botanix Pharmaceuticals has
53 employees.
View email and phone details for 53
employees at Botanix Pharmaceuticals.
Botanix Pharmaceuticals's industry is
Pharmaceutical Manufacturing
Botanix Pharmaceuticals's top competitors are
Abbvie,
Ionis Pharmaceuticals, Inc.,
Dermavant Sciences, An Organon Company,
Vertex Pharmaceuticals,
Little Green Pharma,
Mix Talent,
Sun Pharma,
Arcutis Biotherapeutics, Inc. (Nasdaq: Arqt),
Galderma,
Incyte.
Botanix Pharmaceuticals's categories are Pharmaceutical Manufacturing
